Feedback

British drugmaker to deliver 400 million doses of coronavirus vaccine to Europe

Source : 112 Ukraine

The company has already concluded an agreement with the governments of the countries of the region
22:17, 14 June 2020

Open source

AstraZeneca company has signed a contract with European governments to supply the region with its potential vaccine against the coronavirus, the British drugmaker’s latest deal to pledge its drug to help combat the pandemic. This is reported by Reuters.

The contract is for up to 400 million doses of the vaccine, developed by the University of Oxford, the company said, adding that it was looking to expand the manufacturing of the vaccine, which it said it would provide for no profit during the pandemic. The vaccine is still in clinical trials. If the trial results convince regulators the vaccine is safe and effective, deliveries would be expected to start by the end of 2020.

The deal is the first contract signed by Europe’s Inclusive Vaccines Alliance (IVA), a group formed by France, Germany, Italy, and the Netherlands to secure vaccine doses for all member states as soon as possible.

This will ensure that hundreds of millions of people in Europe will have access to this vaccine, of course, if it works and we will know that by the end of summer,” the company’s chief executive, Pascal Soriot told journalists. He said he has “good hope” that it will work, based on initial data.

The alliance “will work together with the European Commission and other countries in Europe to ensure everybody across Europe is supplied with the vaccine,” he said.

“We have a very self-sufficient supply chain for Europe” with manufacturers lined up in the Netherlands, Germany, Italy, and Italy, among others, he said.

Related: Coronavirus in Ukraine dashboard: online

The vaccines are for all EU member states. The four nations that agreed the deal will pay for the total amount, which has not been disclosed, and the scheme allows other countries to join it under the same conditions, a source from the Italian health ministry said.

China, Brazil, Japan, and Russia have also expressed interest, he said.

The British Medicines and Healthcare products Regulatory Agency (MHRA) has approved the start of Phase III trials of the vaccine after studies showed sufficient efficacy and safety, Soriot said.

At a meeting of EU Health Ministers on Friday, IVA agreed to merge its activities with those of the EU Commission, Germany’s Health Ministry said.

The deal is the latest by AstraZeneca to promise to supply its vaccine to governments who have scrambled to agree on advance purchases of promising coronavirus immunization treatments.

Related: Prosecutors question Italy’s PM Conte over Lombardy lockdown

Topics:
Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

Comments
see more